Clarivate

Global Pharma And AI Trends Will Build Future Growth

AnalystConsensusTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

11 May 25

Updated

08 Aug 25

AnalystConsensusTarget's Fair Value

US$5.14

21.9% undervalued

08 Aug

US$4.02

-35.2%

8.9%

Author's Valuation

US$5.1

21.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$5.1

21.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.61%

Professional Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.04%

Calculation

US$11.28m

Earnings '28

338.41x

PE Ratio '28

US$3.82b

Market Cap '28

US$3.82b

Market Cap '28

540.70m

No. shares '28

US$7.06

Share Price '28

US$7.06 Share Price '28

Discounted to 2025 @ 11.18% p.a.

US$5.14

Fair Value '25